Advancing host-directed therapy for tuberculosis: new therapeutic insights from the Toxoplasma gondii
Authors:Chul-Su Yang
doi: 10.15698/mic2017.03.565
Volume 4, pp. 105 to 107, published 02/03/2017.
1 Department of Molecular and Life Science, Hanyang University, Ansan 15588, S. Korea.
2 Department of Bio-nanotechnology, Hanyang University, Seoul, 04673, S. Korea.
Keywords:
Toxoplasma gondii, GRA7, macrophages, protein-protein interactions, Mycobacterium tuberculosis.
Corresponding Author(s):
Conflict of interest statement:
The authors declare that they have no conflict of interest.
Please cite this article as:
Chul-Su Yang (2017). Advancing host-directed therapy for tuberculosis: new therapeutic insights from the Toxoplasma gondii. Microbial Cell 4(3): 105-107.
© 2017 Yang. This is an open-access article released under the terms of the Creative Commons Attribution (CC BY) license, which allows the unrestricted use, distribution, and reproduction in any medium, provided the original author and source are acknowledged.
Abstract:
Tuberculosis (TB) drug-development strategies, a wide range of candidate host-directed therapies (HDT)s-including new and repurposed drugs, biologics, and cellular therapies-have been proposed to accelerate eradication of infection and overcome the problems associated with current treatment regimens. By investigating the interaction between macrophages and the intracellular parasite Toxoplasma gondii (T. gondii), we uncovered that infection-induced signaling pathways suggest possibilities for the development of novel therapeutic modalities for TB that target the intracellular signaling pathways permitting the replication of Mycobacterium tuberculosis (MTB).